ERBB2 and cholangiocarcinoma: Based on these findings (inclusive data from DESTINY-Lung01; DESTINY-CRC02) the FDA approved TDx for unresectable or metastatic HER2-positive (IHC 3+) solid tumors, including advanced cholangiocarcinoma.